After winning FDA approval for exclusive rights to sell Makena, a drug that prevents preterm labor, reported Associated Press, KV Pharmaceutical raised the price from $10 to 20 per injection to $1,500. About 130,000 women a year are estimated to benefit from the drug but many state Medicaid programs are unable to afford the higher price.